z-logo
Premium
Expression and distribution of kinin B 1 receptor in the rat brain and alterations induced by diabetes in the model of streptozotocin
Author(s) -
Campos Maria Martha,
Ongali Brice,
De Souza Buck Hudson,
Schanstra JoostPeter,
Girolami JeanPierre,
Chabot JeanGuy,
Couture Réjean
Publication year - 2005
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.20150
Subject(s) - medicine , streptozotocin , endocrinology , receptor , in situ hybridization , hippocampus , riboprobe , radioligand , kinin , piriform cortex , biology , chemistry , messenger rna , diabetes mellitus , bradykinin , biochemistry , gene
A role for kinin B 1 receptors was suggested in the spinal cord and peripheral organs of streptozotocin (STZ)‐diabetic rats. The present study aims at determining whether B 1 receptors are also induced and over‐expressed in the brain of STZ‐rats at 2, 7, and 21 days post‐treatment. This was addressed by in situ hybridization using the [ 35 S]‐UTPαS‐labeled riboprobe and by in vitro autoradiography with the radioligand [ 125 I]‐HPP‐des‐Arg 10 ‐Hoe 140. In control rats, B 1 receptor mRNA was found widely distributed in many brain regions. Low mRNA levels were found in thalamus and hypothalamus (7–12 nCi/g) while high mRNA signals were detected in cortical regions and hippocampus (18–29 nCi/g). In diabetic rats, B 1 receptor mRNA was markedly increased in hippocampus, temporal/parietal cortices and amygdala at 2 and 7 days (+88 to +150%). Low densities of B 1 receptor binding sites were detected in all analyzed regions in control rats (0.18–0.37 fmol/mg tissue). In diabetic rats, B 1 receptor binding sites were significantly increased in hippocampus, amygdala, temporal/parietal, and perhinal/piriform cortices (+ 55 to + 165 %) at 7 days only. Results highlight an early but transient and reversible up‐regulation of B 1 receptors in specific brain regions of STZ‐diabetic rats. This may offer the advantage of reducing putative central side effects with B 1 receptor antagonists if used for the treatment of diabetic complications in the periphery. Synapse 57:29–37, 2005. © 2005 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom